Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2023-03-13 Regulatory Filings
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
DEF 14C
Regulatory Filings Classification · 95% confidence The document is a Schedule 14C Information Statement filed pursuant to Section 14(c) of the Securities Exchange Act of 1934. It details a stockholder action by written consent approving a reverse stock split of the company's common stock. The document explicitly states it is an Information Statement, not a proxy solicitation, and it informs stockholders of corporate actions taken without a meeting. The content focuses on corporate governance actions related to stockholder voting and amendments to the certificate of incorporation, specifically about a reverse stock split. There are no financial statements, earnings data, or audit information. The document is not a proxy solicitation (DEF 14A) but an information statement pursuant to Schedule 14C. This type of filing is best classified under Regulatory Filings (RNS) as it is a regulatory announcement informing shareholders of corporate actions without a meeting and does not fit other more specific categories such as MANG or SHA. The document length and detail confirm it is not a brief announcement but a formal regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-03-13 English
PRE 14C
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14C Information Statement filed with the SEC, pursuant to Section 14(c) of the Securities Exchange Act of 1934. It informs stockholders of Mustang Bio, Inc. about a stockholder action taken by written consent to approve a reverse stock split of the company's common stock. The document explicitly states it is an Information Statement, not a proxy solicitation, and it provides detailed information about the stockholder action, voting, and the reverse stock split amendment. This type of filing is used to inform shareholders of corporate actions without a meeting and is classified as a Proxy Solicitation & Information Statement (PSI). It is not an announcement of voting results (DVA) because it is the statement accompanying the written consent action, nor is it a capital change announcement (SHA) because it is a formal information statement under SEC rules. Therefore, the correct classification is PSI with high confidence.
2023-03-03 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 3, 2023, by Mustang Bio, Inc. It reports the submission of matters to a vote of security holders, specifically the approval of a reverse stock split by written consent of shareholders. The content focuses on the voting results and the board's authority to effect the reverse stock split. There is no detailed financial data or comprehensive report content, but rather an announcement of shareholder voting results and related corporate action. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4631 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Therefore, the appropriate classification is DVA with high confidence.
2023-03-03 English
SC 13D/A
Major Shareholding Notification
2023-01-13 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-01-07 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses the entry into a material definitive agreement, namely a First Amendment to a Loan and Security Agreement, which involves changes to the loan terms including replacement of LIBOR with SOFR rates. This is a financing-related update. The document does not contain full financial statements or detailed financial performance data, but rather an announcement of a financing amendment. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about the financing amendment, not just a notice or link to a report, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2022-12-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.